Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide.
GID
2 followers
Merck
347 followers
PTC Therapeutics
13 followers
Mountainside
3 followers
Health Career Connection
1 follower
Dimension
1 follower
Methodist Health System
2 followers
Johnson & Johnson
669 followers
Blueprint Medicines
6 followers
Thermo Fisher Scientific
284 followers
Genentech
226 followers
Gilead Sciences
213 followers